C. Peschel

421 total citations
41 papers, 332 citations indexed

About

C. Peschel is a scholar working on Hematology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, C. Peschel has authored 41 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Oncology. Recurrent topics in C. Peschel's work include Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Erythrocyte Function and Pathophysiology (5 papers). C. Peschel is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Erythrocyte Function and Pathophysiology (5 papers). C. Peschel collaborates with scholars based in Germany, Austria and France. C. Peschel's co-authors include D. Geißler, G Konwalinka, H Braunsteiner, C. Huber, M. Wenczl, Magdolna Dank, J. Załuski, Marie‐Laure Risse, R. Bugat and Erdem Göker and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Haematology and Endoscopy.

In The Last Decade

C. Peschel

38 papers receiving 322 citations

Peers

C. Peschel

PRM

HEMAT

ONCOL

SURGE

GENET

H.J. Weh Germany

Monica V.E. Gallivan United States

Athina Androulaki Greece

Mohammed Shaik United States

Françoise Delacrétaz Switzerland

Mariko Yabe United States

P.P. Bapsy India

Mark Tuthill United Kingdom

Yi‐Fang Chang Taiwan

Zimu Gong United States

H.J. Weh Germany

C. Peschel

143 ×1.0

PRM

182 ×1.4

HEMAT

257 ×2.4

ONCOL

65 ×0.8

SURGE

86 ×1.1

GENET

Citations per year, relative to C. Peschel C. Peschel (= 1×) peers H.J. Weh

Countries citing papers authored by C. Peschel

Since Specialization

Citations

This map shows the geographic impact of C. Peschel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Peschel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Peschel more than expected).

Fields of papers citing papers by C. Peschel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Peschel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Peschel. The network helps show where C. Peschel may publish in the future.

Co-authorship network of co-authors of C. Peschel

This figure shows the co-authorship network connecting the top 25 collaborators of C. Peschel. A scholar is included among the top collaborators of C. Peschel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Peschel. C. Peschel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lordick, Florian, Ken Herrmann, Hans Geinitz, et al.. (2011). PET-guided treatment in locally advanced adenocarcinoma of the esophagogastric junction (AEG): The MUNICON-II study.. Journal of Clinical Oncology. 29(4_suppl). 3–3. 5 indexed citations

Lordick, Florian, Sylvie Lorenzen, S. Al-Batran, et al.. (2008). Cetuximab and cisplatin/5-FU (CF) versus CF in first-line metastatic squamous cell carcinoma of the esophagus (MESCC): A randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Journal of Clinical Oncology. 26(15_suppl). 4546–4546. 9 indexed citations

Lorenzen, Sylvie, Ken Herrmann, Wolfgang Weber, et al.. (2007). Visualisation of metastatic oesophageal and gastric cancer and prediction of clinical response to palliative chemotherapy using 18FDG PET. Nuklearmedizin - NuclearMedicine. 46(6). 263–70. 5 indexed citations

Witzig, Richard, U. Fink, Harald Gündel, et al.. (2006). Delays in diagnosis and therapy of gastric cancer and esophageal adenocarcinoma. Endoscopy. 38(11). 1122–1126. 14 indexed citations

Gottschalk, Nina, Robert A.J. Oostendorp, C. Peschel, et al.. (2005). Das STEMMAT-Projekt als Teil der Gesundheitsinitiative BayernAktiv: Adulte Stammzellen aus Nabelschnur und -blut als Alternative zur embryonalen Stammzellforschung. Zentralblatt für Gynäkologie. 127(6). 368–372. 4 indexed citations

Lordick, Florian, Angela Ihbe‐Heffinger, & C. Peschel. (2005). Antiemetische Prophylaxe bei der Chemotherapie gastrointestinaler Tumoren. Zeitschrift für Gastroenterologie. 43(4). 391–398.

Duyster, Justus, Sylvie Lorenzen, Frank Kullmann, et al.. (2005). Oxaliplatin plus 5FU/folinic acid (FUFOX Regimen) in 1^st line metastatic gastric cancer (MGC). Results of the Multicenter Phase II STOMOX Trial. Journal of Clinical Oncology. 23(16_suppl). 4016–4016. 3 indexed citations

Oostendorp, Robert A.J., et al.. (2004). Maintenance of hematopoietic stem cells does not require direct contact with embryo-derived stromal cells in co-cultures. mediaTUM (Technical University of Munich). 3 indexed citations

Siess, M., R. Bumm, M. Molls, C. Peschel, & J. R. Siewert. (2002). Qualitätsmanagement und Erfahrungen mit dem „Cancer Center“. DMW - Deutsche Medizinische Wochenschrift. 127(17). 896–900. 6 indexed citations

10.

Schneller, Folker, Martin Schüler, Kurt R. Schumacher, et al.. (1998). Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia - results of a phase-II trial. Annals of Hematology. 77(5). 225–229. 4 indexed citations

11.

Aulitzky, W. E., C. Peschel, Folker Schneller, & Christian G. Huber. (1995). Biotherapy of chronic myelogenous leukemia. Annals of Hematology. 70(3). 113–120. 1 indexed citations

12.

Aulitzky, W. E., C. Peschel, Folker Schneller, & C. Huber. (1995). Biotherapy of chronic myelogenous leukemia. Annals of Hematology. 70(3). 113–120. 9 indexed citations

13.

Despres, Daryl, Jutta Goldschmitt, W. E. Aulitzky, C. Huber, & C. Peschel. (1995). Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.. PubMed. 23(14). 1431–8. 8 indexed citations

14.

Aulitzky, W. E., C. Peschel, Daryl Despres, et al.. (1993). Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia. Annals of Hematology. 67(5). 205–211. 10 indexed citations

15.

Konwalinka, G, et al.. (1986). Effect of human plasmalipoproteins on erythropoietic progenitor cells in serum-free cultures. Annals of Hematology. 52(3). 191–195. 2 indexed citations

16.

Konwalinka, G, et al.. (1986). Human erythropoiesis in vitro and the source of burst-promoting activity in a serum-free system.. PubMed. 14(10). 899–903. 15 indexed citations

17.

Peschel, C., G Konwalinka, D. Geißler, & H Braunsteiner. (1986). In vitro growth of erythropoietic progenitor cells in long‐term remission of acute leukemia. The International Journal Of Cell Cloning. 4(3). 186–191. 3 indexed citations

18.

Konwalinka, G, et al.. (1984). A miniaturized agar culture system for cloning human erythropoietic progenitor cells.. PubMed. 12(1). 75–9. 13 indexed citations

19.

Geißler, D., C. Peschel, & G Konwalinka. (1983). [New aspects of megakaryopoiesis].. PubMed. 95(19). 685–8. 1 indexed citations

20.

Konwalinka, G, D. Geißler, C. Peschel, et al.. (1982). A micro agar culture system for cloning human erythropoietic progenitors in vitro.. PubMed. 10(1). 71–7. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact